LL LLY Eli Lilly and Company Loading... : Bullish and Bearish Analyst Opinions

GLP-1 distribution revenues declined 4% sequentially in Q4, though still up 22% YoY, indicating a potential plateau in the rapid growth phase. — A sequential decline in GLP-1 volumes could signal maturation in the weight-loss drug market, potentially impacting the revenue growth outlook for manufacturers and suppliers.

GLP-1 distribution revenue of $14 billion in the quarter grew 26% year-over-year but only 7% sequentially, indicating a rapid deceleration from the high double-digit sequential growth rates seen in prior quarters. — The deceleration in GLP-1 growth suggests the distribution boost from injectables is plateauing, and while oral GLP-1s are a new opportunity, they are not yet compensating for the pace of injectable growth.